Amphastar Pharmaceuticals, Inc. (AMPH): Jason B. Shandell , President and General Counsel of Amphastar Pharmaceuticals, Inc. sold 56,996 shares on Sep 26, 2016. The Insider selling transaction was reported by the company on Sep 27, 2016 to the Securities and Exchange Commission. The shares were sold at $19.50 per share for a total value of $1,111,268.12 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 12, 2016, Floyd F. Petersen (director) sold 3,000 shares at $19.05 per share price.On Sep 2, 2016, Howard Lee (director) sold 10,381 shares at $18.78 per share price.Also, On Aug 24, 2016, Jason B. Shandell (President and General Counsel) sold 10,000 shares at $19.95 per share price.On Aug 19, 2016, Richard K Prins (director) sold 3,086 shares at $19.62 per share price.
Shares of Amphastar Pharmaceuticals Inc (AMPH) ended Thursday, Sep 22, 2016 session in red amid volatile trading. The shares closed down -1.15 points or -5.50% at $19.75 with 13,14,352 shares getting traded. Post opening the session at $20.96, the shares hit an intraday low of $19.65 and an intraday high of $21.11 and the price vacillated in this range throughout the day. The company has a market cap of $891 M and the number of outstanding shares has been calculated to be 4,51,21,158 shares. The 52-week high of Amphastar Pharmaceuticals Inc is $21.53 and the 52-week low is $10.5.
Company has been under the radar of several Street Analysts.Amphastar Pharmaceuticals Inc is Reiterated by Needham to Buy and the brokerage firm has raised the Price Target to $ 22 from a previous price target of $20 .The Rating was issued on Aug 9, 2016.
Amphastar Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing manufacturing marketing and selling technically-challenging generic and injectable and inhalation products. The Company has two operational segments: finished pharmaceutical products and active pharmaceutical ingredients (API products). The finished pharmaceutical products segment manufactures markets and distributes enoxaparin Cortrosyn naloxone lidocaine jelly as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company manufactures and sells approximately 17 products and is developing a portfolio of approximately 13 generic and eight injectable and inhalation product candidates. In addition to its marketed products it has a pipeline of approximately 21 generic and product candidates in various stages of development which target a variety of indications.